Maze Therapeutics prices $144.7M equity offering to fund drug development through 2029

Filed April 22, 2026 · Period ending April 21, 2026 · ~1 min read

Key Changes

• high

  Company sold 5.54M shares at $23.50 and 850K pre-funded warrants at $23.499, netting $144.7M after fees—immediate dilution of roughly 6.4M shares to existing holders.

  Item 1.01 view on EDGAR →
• high

  Proceeds will primarily fund R&D for two drug candidates: MZE829 for kidney disease and MZE782 for PKU and chronic kidney disease, plus general corporate use.

  Item 1.01 view on EDGAR →
• high

  Combined with existing cash, the offering extends operational runway into 2029, eliminating near-term financing risk for approximately $23.50 three years.

  Item 1.01 view on EDGAR →